Product Program year 2024 Source: CMS Open Payments

Ponvory

Drug Neuroscience

NDC 50458-707-14

Open in the dashboard

General payments

$1,189,031

13,234 payments

Research payments

$0

0 payments

Through program year 2024, $1,189,031 in general payments and $0 in research payments were reported against Ponvory (Neuroscience).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2024 General $1,913 2
2023 General $41,585 708
2022 General $1,041,981 11,587
2021 General $103,552 937

Breakdown

Who paid General payments · program years 2021–2024
  1. Janssen Pharmaceuticals, Inc $1,111,775 13,129 payments
  2. Janssen Scientific Affairs, LLC $44,191 79 payments
  3. Janssen Global Services, LLC $29,580 21 payments
  4. Johnson & Johnson Health Care Systems Inc. $2,336 4 payments
  5. Janssen Research & Development, LLC $1,150 1 payment
Top recipients General payments · program year 2024
  1. David Dunner Psychiatry · Mercer Island, WA $1,913 100% · 2 payments

Each share is of general payments naming this product in 2024.

Specialties paid General payments · program year 2024
  1. Psychiatry Psychiatry & Neurology $1,913 100% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2024
  1. Washington $1,913 100% · 1 recipient

Each share is of general payments naming this product in 2024 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

254

Prescriptions dispensed, refills included

Drug cost

$2,349,790

Paid at the pharmacy, in all

Prescribers

19

With 11 or more claims of it

Medicare Part D drugs matched to Ponvory, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Ponvory Ponesimod Same name 19 254 $2,349,790

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 19 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Clara Zelasky Physician Assistant NC 24 $215,159 None on record
Carrie Downey Neurology ME 23 $203,683 None on record
Robyn Young Neurology CA 14 $132,252 $18
Brandee Fonseca Nurse Practitioner NJ 14 $131,317 $35
Jae Eun Lee Neurology KY 13 $126,805 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See all 19 in the dashboard with a free account
13,234 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record